In today’s pharmaceutical and healthcare market, consumers look beyond mere efficacy or external appearance; they are becoming increasingly stringent regarding origin, safety, and quality control processes. Deeply understanding that customer trust is an invaluable asset, Sum Pharmaceutical Investment Joint Stock Company (Sumpharma) always aligns its product development with the criteria of being cautious, selective, and comprehensively controlled from the root.
To realize that commitment, during business trips in late 2025 and early 2026, Ms. Nguyen Thi Phuong Loan – Chairwoman of the Board of Directors of Sumpharma – personally led a delegation to visit, survey, and work at strategic factories and manufacturing units both domestically and internationally (including leading partners in Europe).
Hands-on and Close Inspection – No Compromise on Quality from Afar
At Sumpharma, we do not select suppliers or partners based solely on beautiful corporate profiles or negotiations through a computer screen. For health products, quality is not determined only by the final product, but by the entire operational workflow, the manufacturing environment, and the actual capacity of the factory.
The direct presence of Chairwoman Nguyen Thi Phuong Loan at our partners’ production lines reinforces the hands-on, rigorous working style and the highest sense of responsibility held by Sumpharma’s executive board for every product launched into the market.
Comprehensive Assessment Under Strict Standards
Through these field surveys, Sumpharma’s professional team directly evaluated and verified:
-
Operational Process: Ensuring that all manufacturing steps, from raw materials input to packaging, meet international quality standards and the stringent certifications of the medical and pharmaceutical industry.
-
Quality Control System: Assessing the capacity of the on-site testing laboratories, risk control capabilities, and the uniformity of each batch.
-
Vision and Technology: Engaging in open discussions with experts and manufacturing representatives regarding technological development directions and updating advanced scientific trends to optimize product efficacy.
The straightforward exchanges and mutual understanding between Sumpharma and both European and domestic manufacturers serve as the launching pad for building long-term, sustainable, and strategic partnerships.
Product Direction: Leveraging Quality as the “Fulcrum” for Growth
This cautious and selective approach helps Sumpharma avoid rushed decisions, creating a solid foundation for expanding its product portfolio and capturing market share. The practical insights gained from these business trips provide multi-dimensional perspectives, helping the company continuously refine its partner evaluation criteria and optimize its healthcare product ecosystem.
In the journey ahead, Sumpharma commits to further expanding cooperation with manufacturers that possess outstanding capacity, heart, and vision. From there, we aim to bring high-quality, absolutely safe product lines to Vietnamese consumers, fully meeting the community’s needs for health protection and improvement.
Sumpharma – Quality from the root, confidently pioneering!
